| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With… |
Trial sites expanded: 459 -> 475 locations |
| 2026-06-12 | NCT07599345 Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data |
Primary endpoint(s) modified |
| 2026-06-12 | NCT07599293 Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data |
Primary endpoint(s) modified |
| 2026-06-11 | NCT07064473 EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin… |
Trial sites expanded: 1152 -> 1155 locations |
| 2026-06-10 | NCT07214818 SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-05 | NCT06674109 SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial |
Recruitment opened |
| 2026-06-03 | NCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With… |
Trial sites expanded: 452 -> 459 locations |
| 2026-06-03 | NCT06935370 A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps… |
Trial sites reduced: 639 -> 635 locations |
| 2026-06-02 | NCT07572032 Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology… |
Recruitment opened |
| 2026-05-23 | NCT06171802 EMPagliflozin After Aortic Valve Replacement |
Trial completed |
| 2026-05-21 | NCT07594145 Precision T1D Platform - New Therapies for Cardio-Renal Complications |
Primary endpoint(s) modified |
| 2026-05-14 | NCT06844669 HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… |
Trial terminated |
| 2026-05-14 | NCT06844669 HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… |
critical why stopped: null → "Futility" |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07628556 Antidiabetic Medications and Risk of Cancer | Completed | |
| 2026-05-20 | NCT07599293 Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data | Active, Not Recruiting | |
| 2026-05-20 | NCT07599345 Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data | Active, Not Recruiting | |
| 2026-05-18 | NCT07594145 Precision T1D Platform - New Therapies for Cardio-Renal Complications | Phase 2 | Not Yet Recruiting |
| 2026-05-15 | NCT07591077 SGLT2 Adjunct in T1D | Phase 2/3 | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05164263 | Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in… | Type II Diabetes Mellitus | Recruiting |
| NCT06625073 | Randomized Trial of SGLT2i in Heart Transplant Recipients | Heart Transplant | Recruiting |
| NCT06055452 | Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension | Pre-Heart Failure | Recruiting |
| NCT06013865 | Empagliflozin Treatment in Kidney Transplant Recipients | Kidney Transplant | Recruiting |
| NCT06613854 | Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in… | Type 2 Diabetes Mellitus (T2DM) | Recruiting |
| NCT05671991 | Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease | End Stage Renal Disease on Dialysis | Recruiting |
| NCT07572032 | Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology… | Heart Failure Due to Coronary Artery Disease | Recruiting |
| NCT06674109 | SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial | Gout and Hyperuricemia | Recruiting |
| NCT07325435 | Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and… | Type 2 Diabetes (T2DM) | Active, Not Recruiting |
| NCT05426525 | Use of Empagliflozin to Treat Prediabetes | PreDiabetes | Active, Not Recruiting |
| NCT07074418 | Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 | Chronic Kidney Diseases | Not Yet Recruiting |
| NCT07365358 | Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in… | Diabete Type 2 | Not Yet Recruiting |
| NCT05147090 | Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients | Chronic Hepatitis b | Active, Not Recruiting |
| NCT06851962 | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. | Diabetes Mellitus Type 2 | Active, Not Recruiting |
| NCT07547878 | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Chronic Kidney Disease | Not Yet Recruiting |
| NCT07228195 | SGLT2i Therapy in Islet Transplantation (SIT) | Partial Islet Function | Not Yet Recruiting |
| Phase 3 | |||
| NCT05669742 | Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in… | Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics | Recruiting |
| NCT05392764 | Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients… | Acute Heart Failure | Recruiting |
| NCT06217302 | Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and… | Diabetic Nephropathies | Recruiting |
| NCT07038356 | Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on… | Acute Decompensated Heart Failure (ADHF) | Recruiting |
| NCT04381936 | Randomised Evaluation of COVID-19 Therapy | Pneumonia | Recruiting |
| NCT05715814 | meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis | Peritoneal Dialysis Complication | Recruiting |
| NCT06481891 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive… | Obstructive Cardiomyopathy, Hypertrophic | Recruiting |
| NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With… | Heart Failure | Recruiting |
| NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps… | Heart Failure | Recruiting |